Description
Modern cancer therapies target specific cell processes. The development of monoclonal antibodies binding to epidermal growth factor receptor (EGFR) and the development of drugs inhibiting EGFR tyrosine kinase have been major steps towards personalized cancer treatment.
Targeted therapy generally causes less damage to healthy cells compared to conventional chemotherapy.
Optimal results in cancer treatment are achieved when the personalized approach is chosen.
Monoclonal antibody and tyrosine kinase inhibitor therapies work exceptionally well in many, but not in all cases. Treatment response is highly dependent on the genetic profile of the tumor.
Thus, genetic tests identifying relevant mutations in oncogenes and tumor suppressor genes facilitate an efficient patient-specific therapy.
Reviews
There are no reviews yet.